Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.

Julia K. Rotow, Xiuning Le, Anastasios Dimou et al.|Journal of Clinical Oncology|2026

Cited by 0